Tat protein, a trans-activating factor of the human immunodeficiency virus type 1, acts also as an extracellular molecule modulating gene expression, cell survival, growth, transformation, and angiogenesis. Here we demonstrate that human thrombospondin-1 (TSP), a plasma glycoprotein and constituent of the extracellular matrix, binds to glutathione-S-transferase (GST)-Tat protein but not to GST. Scatchard plot analysis of the binding of free GST-Tat to immobilized TSP reveals a highaffinity interaction (K d equal to 25 nM). Accordingly, TSP inhibits cell internalization and HIV-1 LTR trans-activating activity of extracellular Tat in HL3T1 cells with ID 50 equal to 10 -30 nM. Also, TSP inhibits cell interaction and mitogenic activity of extracellular Tat in T53 Tat-less cells. TSP is instead ineffective when administered after the interaction of Tat with cell surface heparan-sulfate proteoglycans has occurred, in keeping with its ability to prevent but not disrupt Tat/heparin interaction in vitro. Finally, TSP inhibits the autocrine loop of stimulation exerted by endogenous Tat in parental T53 cells. Accordingly, TSP overexpression inhibits cell proliferation, angiogenic activity, and tumorigenic capacity of stable T53 transfectants. Our data demonstrate the ability of TSP to bind to Tat protein and to affect its LTR trans-activating, mitogenic, angiogenic, and tumorigenic activity. These findings suggest that TSP may be implicated in the progression of AIDS and in AIDS-associated pathologies by modulating the bioavailability and biological activity of extracellular
TAT is a viral regulatory gene of the human immunodeficency virus type 1 (HIV-1), the etiologic agent of AIDS (1, 2) . The HIV-1 Tat protein is an 86 -101 amino acid polypeptide, depending on the virus strain, which is encoded by two exons and translated from multiply spliced 2 kb mRNAs (3) .
Tat is released from HIV-1-infected cells (4) . Extracellular Tat has the ability to enter the cell and nucleus in an active form where it stimulates the transcriptional activity of HIV-LTR (5) and transactivates endogenous genes (ref 6 and references therein). Moreover, extracellular Tat acts as a pleiotropic molecule inducing several biological effects on target uninfected cells. Tat appears to be responsible, at least in part, for the observed increased incidence of tumors in AIDS patients (7, 8) . Indeed, Tat-transgenic mice develop tumors with different histotypes (9 -11) . Also, Tat protein trans-activates cellular proto-oncogenes and the genome of oncogenic viruses (12) (13) (14) , induces cell immortalization (15) , prevents apoptosis in different cell types (16, 17) , and induces their proliferation (17) (18) (19) . Finally, Tat stimulates angiogenesis (19) that is required for tumor growth and metastasis. Tat has been implicated in the development of Kaposi's sarcoma (KS) (20, 21) , a hypervascularized lesion frequently observed in male AIDS patients (22) .
Tat interacts with at least three classes of cell surface receptors present on different target cells: cell adhesion receptors of the integrin family (18) , the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR (19, 23) , and the chemokine recep-tors CCR2 and CCR3 (24) . Interaction of extracellular Tat with these receptors may activate various intracellular signaling pathways responsible for the biological responses elicited by this protein in target cells (24 -28) . Moreover, Tat is a heparin binding growth factor (29 -31) , and heparan sulfate (HS) proteoglycans (HSPGs) mediate the interaction of Tat with the cell surface (32) and its accumulation in the extracellular matrix (ECM) (33) . HSPGs are also required for Tat internalization and consequent HIV-LTR trans-activation (29 -31; M. Tyagi et al., unpublished observations). Conversely, free heparin inhibits the uptake of extracellular Tat and its HIV-LTR trans-activating activity (29 -31) , modulates the angiogenic activity of Tat in vitro and in vivo (32) , and affects cell surface interaction, mitogenic activity, and protease-inducing activity exerted by Tat protein in murine adenocarcinoma T53 cells (6, 30, 31) . Finally, other ECM components, including fibronectin, fibrinogen, and vitronectin, modulate the biological activity of Tat in different cell types (34, 35) .
Platelet thrombospondin-1 (TSP) is a heparin binding trimeric protein of 440 kDa secreted by several cell types including endothelial and inflammatory cells (36 -39) . In vivo TSP is found as a free molecule or in a cell-associated, HSPG-bound form (40 -42) . Multiple and sometimes opposite functions have been attributed to TSP. Indeed, it both promotes and inhibits cell adhesion, motility, and proliferation of different cell types (43) (44) (45) (46) . Also, TSP production appears to be inversely correlated to the angiogenic and tumorigenic potential of neoplastic cells (47, 48) and TSP inhibits tumorigenesis and angiogenesis in different in vitro and in vivo models (48 -52) . The pleiotropic effects of TSP are probably the consequence of its modular structure, which enables TSP to bind to specific cell receptors and to growth factors and enzymes, such as basic fibroblast growth factor (FGF2) (53) , hepatocyte growth factor/scatter factor (HGF) (54) , transforming growth factor-␤ (TGF-␤) (55) , platelet derived growth factor (PDGF) (56) , and several proteinases (57) .
Recent observations have shown that TSP also inhibits the mitogenic and chemotactic activity exerted by Tat protein on endothelial cells in culture and modulates its angiogenic activity in vivo (58) . In the present paper, we investigated the capacity of TSP to bind directly to HIV-Tat protein and to modulate its bioavailability to target cells. The results demonstrate that TSP binds with high affinity to Tat. This interaction sequesters Tat protein in the extracellular environment and prevents its biological activity in different in vitro and in vivo experimental systems. Thus, TSP appears to be an important regulator of the biological functions of extracellular Tat protein.
MATERIALS AND METHODS

Reagents
TSP was purified from the supernatant of thrombin-stimulated fresh human platelets (59) . The purity was higher than 90% as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), with TGF-␤ contamination being lower than 0,02%. The rabbit polyclonal anti-TSP antibody has been described (53) . Briefly, it recognizes TSP (0,034 -1 pmol) but not fibronectin or type IV collagen at 1:1000 dilution in enzyme-linked immunoassay (ELISA). The neutralizing anti-Tat antiserum was provided by A. Corallini (University of Ferrara, Italy). Recombinant HIV-1 Tat has been expressed in Escherichia coli as glutathione-S-transferase (GST) fusion protein. The corresponding plasmid construct derives from pGST-Tat 2E, originally obtained by cloning the coding region of both exons of HIV-1HXB2 Tat in the commercial vector pGEX2T (60) . This construct codes for the 86 amino acid Tat protein. Recombinant GST-Tat was also fused at its carboxyl terminus to the green fluorescent protein (GFP) as already described (31) . Purification of recombinant GST, GST-Tat, and GST-Tat-GFP proteins was performed by glutathione-agarose affinity chromatography (60, 61) . The purity (Ͼ95%) and integrity of the proteins were routinely checked by SDS-PAGE and silver staining. Bacterial lipopolysaccharide contamination was Յ 1% and heating completely destroyed the biological activity of GST-Tat preparations in all the assays. Previous studies have shown that the GST and GFP moieties do not interfere with the LTR trans-activating activity of Tat and its capacity to bind heparin (29, 31 , and data not shown).
Recombinant GST-Tat was labeled with [ 125 I] (17 Ci/mg, New England Nuclear, Boston, Mass.) using Iodogen (Pierce Chemical Co., Rockford, Ill.) to a specific radioactivity of 400 cpm/fmol as described (30) .
Gel permeation chromatography
TSP (2.3 pmol), GST-Tat (23 pmol), or a mixture of 16 pmol of TSP plus 23 pmol of GST-Tat, each in a final volume of 100 l in 10 mM phosphate buffer, pH 7.3, containing 0.15 M NaCl (PBS), was applied on a gel filtration fast protein liquid chromatography Superose-12 column (Pharmacia, Uppsala, Sweden). The column was then eluted with the same buffer at a flow rate of 0.7 ml/min and 0.7 ml fractions were collected; 350 l of each fraction was spotted onto a nitrocellulose membrane and subjected to dot blot analysis using a 1:400 dilution of anti-TSP antiserum or a 1:100 dilution of anti-Tat antiserum. Immunocomplexes were visualized by chemiluminescence using the ECL Western blotting kit (Amersham International, Little Chalfont, U.K.) and quantified by computerized image analysis. Control experiments demonstrated that anti-TSP and anti-Tat antibodies do not cross-react (data not shown).
GST-Tat affinity chromatography
TSP (0.6 pmol) in a final volume of 200 l of PBS was applied onto columns (5ϫ10 mm) of GST or GST-Tat immobilized to glutathione-agarose beads. After extensive washing with PBS, columns were eluted at a flow rate of 0.1 ml/min with a linear gradient of NaCl in PBS. Fractions (0.3 ml) were collected, spotted onto a nitrocellulose membrane, and probed by dot blot analysis with anti-TSP antibody (1:400). Immunocomplexes were visualized and quantified as described above.
I-GST-Tat binding to TSP-or heparin-coated plastic
TSP was adsorbed to 96-wells polystyrene nontissue culture microplates as described (53) . Briefly, wells were incubated for 2 h at 37°C with 40 l aliquots of TSP (100 nM) in TBS (25 mM Tris-HCl pH 7.4 plus 130 mM NaCl). Then wells were washed and overcoated with 1% bovine serum albumin (BSA) in TBS. Under these experimental conditions, up to 7.5% of TSP originally added to the well remain immobilized to the plastic (53) . In parallel experiments, nontissue culture microplates were incubated overnight at 4°C with 50 l aliquots of heparin (30 M in TBS) . After three washes with TBS, wells were incubated for another 30 min at room temperature with 1% BSA in TBS. Experiments performed by using 3 H-heparin as a tracer revealed that up to 37 pmol of heparin are immobilized to the plastic under these experimental conditions. For binding experiments, 100 l aliquots of 125 I-GSTTat (0.54 nM in TBS) were incubated for 2 h at 4°C into TSPor heparin-coated wells in the absence or presence of different competitors. At the end of incubation, wells were washed three times with TBS; Tat-associated radioactivity was solubilized by incubating the wells for 30 min at 50°C with 2% SDS in H 2 O, collected, and measured in a liquid scintillation counter. The amount of 125 I-GST-Tat bound to BSA-coated wells was used as nonspecific binding and was subtracted from all the values.
To determine the K d of the interaction of 125 I-GST-Tat with TSP, 100 l aliquots of TBS containing different concentrations of 125 I-GST-Tat were added to TSP-coated wells. Then samples were processed exactly as described above. Binding data were analyzed by the Scatchard plot procedure (62) .
Cell cultures and TSP cDNA transfection
HL3T1 cells are derived from HeLa cells and contain integrated copies of pL3CAT, a plasmid in which the chloramphenicol acetyltransferase (CAT) bacterial gene is driven by HIV-1 LTR (63). The T53 cell line was established from adenocarcinoma of skin adnexa of Tat-transgenic mice. They produce and secrete biologically active Tat, which in turn stimulates their proliferation (16, 64) . T53 TAT-AS clone 10 cells were obtained by transfection of T53 cells with a plasmid containing an antisense HIV-1 Tat cDNA. This clone is characterized by a 70 -80% decrease of the production of Tat protein when compared to parental T53 cells (6) . T53 Tat-less cells were obtained by subcloning parental T53 cells by the limiting dilution method. Dot blot analysis of the conditioned medium of T53 Tat-less cells performed with anti-Tat antibodies reveals that this clone does not produce detectable amounts of extracellular Tat when compared to parental T53 cells (31) . However, T53 Tat-less cells retain their capacity to respond to extracellular Tat in terms of cell proliferation (see Results).
Parental T53 cells were transfected with the expression vector pCMVNeoTHBS-1 obtained by inserting the 3567 bp human TSP cDNA into pCMVBamNeo under the control of the CMV promoter (a kind gift from P. S. Steeg, NCI, NIH, Bethesda, Md.) (48) . To obtain stable transfectants, T53 cells were plated at 2.5 ϫ 10 3 cells/100 mm plates and transfected with a calcium phosphate precipitate containing 20 g of plasmid DNA and 20 g of salmon sperm DNA. After 72 h, 500 g/ml of G418 sulfate antibiotic (Sigma. St. Louis, Mo.) was added to cell cultures. G418-resistant clones were isolated and tested for Tat and TSP protein expression by dot blot analysis or ELISA assay of the cell supernatants, respectively.
All cell types were grown and maintained in Dulbecco's modified Eagle medium (DMEM) (Life Technologies, Inc., Grand Island, N.Y.) with 10% fetal calf serum (FCS; Life Technologies).
LTR/CAT trans-activation assay
LTR/CAT trans-activation assay was performed as described (29) . Briefly, HL3T1 cells were incubated for 24 h in DMEM containing 10% FCS and 100 M chloroquine in the absence or presence of GST-Tat (5.4 nM) and of increasing concentrations of TSP. Then conditioned medium was removed and cell cultures were incubated for another 24 h in DMEM containing 10% FCS. At the end of incubation, the amount of CAT protein present in the cell extracts was determined by ELISA using the CAT ELISA kit (Boehringer, Mannheim, Germany) according to manufacturer's instructions.
Internalization of 125 I-GST-Tat and GST-Tat-GFP in HL3T1 cells
The evaluation of 125 I-GST-Tat or of GST-Tat-GFP cell internalization was performed as already described (30, 31) . Briefly, for 125 I-GST-Tat, cells were incubated in the absence or presence of TSP for 16 h at 37°C in medium containing 0.15% gelatin and 20 mM HEPES, pH 7.5, and a mixture of 125 I-GST-Tat (0.54 nM) and unlabeled GST-Tat (5.4 nM) used as a carrier (30) . At the end of incubation, cells were washed and lysed. Radioactivity was then measured in the cell extract. Under these experimental conditions, up to 90% of the radioactivity remains associated to the cells after a wash with 2.0 M NaCl in 20 mM sodium acetate pH 4.0, thus demonstrating the intracellular localization of cell-associated 125 I-GST-Tat (31). Nonspecific radioactivity was evaluated by incubating the cells at 4°C with 125 I-GST-Tat (0.54 nM) and a 200-fold molar excess of unlabeled GST-Tat, and subtracted from each experimental point.
For GST-Tat-GFP, HL3T1 cells adherent to glass coverslips were incubated for 6 h at 37°C in DMEM containing 10% FCS and GST-Tat-GFP (5.4 nM) in the absence or presence of different competitors. At the end of incubation, cells were washed twice with 2.0 M NaCl in PBS to remove cell surfacebound fluorescence and fixed. Observations were carried out under a Nikon photomicroscope equipped for epifluorescence and GST-Tat-GFP internalization was quantified by computerized image analysis.
Image analysis
The Image Pro-Plus analysis system (Media Cybernetics, Silver Spring, Md.) was used to quantify the amount of GST-Tat-GFP internalized in HL3T1 cells. Three to six fields were chosen randomly for each experimental condition and input via a TV camera (Sensicam, CCD imaging, Kelheim, Germany) mounted on the microscope, digitalized on a high resolution monitor, and stored within the Pro-Plus analysis system's memory. The amount of GST-Tat-GFP internalized by HL3T1 cells was quantified by counting the intracellular fluorescent granules corresponding to cell lysosomes loaded with the GFP fusion protein.
T53 cell proliferation assays
Parental T53 cells, T53 TAT-AS clone 10 cells, and T53 Tat-less cells were seeded in 96-well dishes at 10,000 cells/cm 2 in DMEM containing 10% FCS. After 24 h, cell cultures were washed twice with DMEM and incubated for 24 h in fresh medium containing 10% FCS in the absence or presence of GST-Tat (2.7 nM) and/or different competitors. At the end of incubation, cells were trypsinized and counted in a Burker chamber.
Chick embryo chorioallantoic membrane (CAM) assay
Fertilized chicken eggs were incubated under constant humidity at 37°C. On the third day of incubation, a window was opened in the eggshell after removal of 2-3 ml of albumen to detach the shell from the developing CAM. The window was sealed with a glass and the eggs were returned to the incubator. On day 8, 10 mm 3 sterilized gelatin sponges (Gelfoam; Upjohn Co., Kalamazoo, Mich.) were implanted on the top of the CAMs under sterile conditions and adsorbed with 10 l of 10% FCS in DMEM alone (negative control) or containing parental T53 cells, TSPtransfected cells, or FGF2-overexpressing mouse aortic endothelial (MAE) pZipFGF2 cells, used here as a positive control (65) . All cell types were tested at 6 ϫ 10 4 or 2 ϫ 10 4 cells/sponge (5-6 embryos per group). CAMs were examined daily until day 12 and photographed in ovo under a Zeiss SR stereomicroscope. The angiogenic response was scored by two investigators without knowledge of the samples tested and graded on an arbitrary scale of 0 -4ϩ, with 0 representing no angiogenic response and 4ϩ representing the strongest activity.
Subcutaneous (s.c.) tumor growth assay
Female NCr-nu/nu mice were obtained from the National Cancer Institute-Frederick Cancer Research and Development Center (Frederick, Md.) and used when 6 -8 wk old. Parental and TSP-transfected T53 cells were harvested by a brief exposure to 0.25% trypsin/0.02% EDTA, washed twice, and resuspended in DMEM. Mice were given a s. c. injection of 1 ϫ 10 6 cells resuspended in 0.2 ml DMEM in the dorsal scapular region (5 animals per group). The tumor mass was measured twice a week with calipers and tumor weight (in grams) was estimated by the formula: (length ϫ width 2 )/2. At death, lesions were removed and divided in two parts: one part was paraffin embedded and tissue sections were stained with hematoxylin and eosin; the other one was processed for immunohistochemical analysis as described below.
Immunohistochemistry and assessment of microvessel density
Tissues were embedded in OCT compound, frozen, and 5 m sections were obtained by a cryostat microtome. For immunolocalization of TSP, sections were rinsed in PBS and incubated for 20 min with 0.3% H 2 O 2 in absolute methanol to block endogenous peroxidase and for a further 20 min with 0.2% Triton X-100 in PBS. Then a 30 min preincubation with diluted normal serum was followed by incubation at 4°C with undiluted monoclonal anti-TSP antibody (58) in a humidified chamber. Sections were then exposed to biotinylated secondary antibody (Vector Laboratories. Burlingame, Calif.) and to avidin-biotin-peroxidase complex (DAKO ABComplex HRP) for 30 min. Peroxidase color reaction was developed with 3-amino-9-ethyl-carbazole (Sigma) and the sections were lightly counterstained with Mayer's hematoxylin.
To detect blood vessels, sections were processed exactly as described above except for the use of a rat anti-murine CD31 antibody (66) replacing the monoclonal anti-TSP antibody. To evaluate microvessel density, sections from each tumor were examined at low-power magnification to identify the areas with the highest density of CD31-positive vessels in the parenchymal and stromal compartments. For both compartments, the most vascularized area was selected and microvessels in a ϫ400 field were counted. Microvessels were defined as any immunoreactive endothelial cell(s) that were separate from adjacent microvessels. Vessel lumens were not necessary for a structure to be defined as a microvessel. No significant differences in microvessel counts were observed between paired sections of individual tumors.
RESULTS
In vitro TSP/Tat interaction
TSP binds to several angiogenic factors, including FGF2, HGF, PDGF, and TGF-␤, and this contributes to its anti-angiogenic activity (53) (54) (55) (56) . Since HIV-1 Tat protein acts like an angiogenic factor (19, 20, 32) and TSP inhibits angiogenesis induced by Tat (58), we assessed the capacity of TSP to bind Tat protein. TSP or GST-Tat was first independently subjected to size exclusion chromatography onto a Superose 12 column. Under these experimental conditions, TSP elutes with the void volume of the column (8 ml) whereas GST-Tat elutes with a retention volume of 14 ml (Fig. 1A) . In contrast, when GST-Tat is incubated with TSP before chromatography and then loaded onto the column, it elutes as a TSP/GST-Tat complex in the void volume (Fig. 1A) . Under the same experimental conditions, ferritin does not affect the chromatographic behavior of GST-Tat and TSP does not alter the chromatographic behavior of cytochrome c, thus supporting the specificity of TSP/Tat interaction (data not shown).
When comparing the elution profiles of GST-Tat samples preincubated with increasing amounts of TSP, we observed the complete disappearance of the peak of free GST-Tat at a TSP:GST-Tat molar ratio equal approximately to 1:3, suggesting that each monomer of the trimeric TSP protein binds one molecule of GST-Tat.
To confirm the capacity of TSP to interact with Tat protein, GST-Tat was immobilized onto agaroseglutathione beads to generate a GST-Tat affinity column, which was then assessed for the capacity to bind free TSP. As shown in Fig. 1B , TSP binds with high affinity to immobilized GST-Tat, from which it is eluted at 0.5 M NaCl. The specificity of the interaction was demonstrated by the incapacity of TSP to bind to immobilized GST protein devoid of the Tat moiety (Fig. 1B) .
TSP exists in both a free and an immobilized form (39 -42) . To assess whether immobilized TSP retains its Tat binding capacity, TSP was adsorbed to plastic and evaluated for its capacity to bind to 125 I-GST-Tat. As shown in Fig. 2A , 125 I-GST-Tat interacts with TSP-coated plastic in a dose-dependent manner, maximal binding obtained when wells were coated with TSP at the concentration of 50 -100 nM. The binding of 125 I-GST-Tat to immobilized TSP is specific since it was inhibited by a molar excess of unlabeled GST-Tat and by anti-Tat antibodies ( Fig.  2A) . On this basis, to determine the relative affinity of TSP/Tat interaction, increasing concentrations of 125 I-GST-Tat were incubated onto TSP-coated wells. At the end of incubation, the amount of 125 I-GST-Tat bound to TSP was measured and the binding data were analyzed by the Scatchard plot procedure (62) . As shown in Fig. 2B 
Effect of heparin on TSP/Tat interaction
Both Tat protein (29 -32) and TSP (39 -42) are heparin binding molecules. It was thus interesting to assess whether heparin affects Tat/TSP interaction. Heparin was added to TSP-coated wells together with or 1 h after 125 I-GST-Tat. As shown in Fig. 3A , free heparin prevents the binding of 125 I-GST-Tat to TSP-coated plastic, being ineffective when added 1 h after the radiolabeled molecule.
In a second set of experiments, heparin was immobilized to plastic and evaluated for its ability to bind 
TSP inhibits HIV-1 LTR trans-activation induced by extracellular Tat in HL3T1 cells
Extracellular Tat protein can enter the cell and reach the nucleus where it stimulates the transcriptional activity of HIV-LTR (5). On this basis, we investigated the possibility that TSP interaction may affect the LTR trans-activating activity of extracellular Tat. To this purpose, HL3T1 cells containing the CAT gene under the control of HIV-1 LTR were treated with GST-Tat in the presence of increasing concentrations of TSP. At the end of treatment, the amount of CAT protein produced by the cells, proportional to the LTR trans-activating activity exerted by GST-Tat, was measured by a CAT ELISA assay. As shown in Fig. 4A , TSP inhibits the transactivating activity exerted by GST-Tat in a dosedependent manner, with an ID 50 equal to 10 nM. TSP inhibited with similar potency the trans-activating activity of GST-Tat when the 86 amino acid Tat moiety was replaced by the 101 amino acid Tat form, a widely distributed form of Tat produced by most primary HIV-1 strains (67) (Fig. 4A) . TGF-␤, potentially present in TSP preparations as a contaminant (55), does not affect the LTR trans-activating activity of GST-Tat in HL3T1 cells when tested at doses of up to 10 ng/ml (data not shown).
To investigate the mechanism(s) of inhibition of the LTR trans-activating activity of Tat, TSP was administered to HL3T1 cells together with GST-Tat or at different times before/after GST-Tat administration. As shown in Fig. 4B , TSP inhibits the LTR trans-activating activity of Tat when added up to 3 h before the administration of GST-Tat and maintained throughout the whole experimental period or when added within the first 15 min after the beginning of GST-Tat treatment. In contrast, the addition of TSP to the cell culture medium 30 min after the beginning of GST-Tat treatment was ineffective, indicating that TSP affects an early event in the interaction of Tat with HL3T1 cells. Note that different Tat antagonists, such as the polyanionic heparin and suramin, retain the capacity to inhibit the trans- 125 I-GST-Tat was allowed to interact with immobilized TSP by a preliminary incubation of 1 h at 4°C, then heparin was added to the wells without changing the medium and incubated for a further 2 h at 4°C (ϩ 1 h). At the end of incubation, the amount of radioactivity associated to the immobilized protein was extracted and measured. B) Effect of free TSP on the binding of GST-Tat to immobilized heparin: 100 l aliquots of 125 I-GST-Tat (0.54 nM) were added to heparin-coated 96-well plates in the absence (Ϫ) or presence (ϩ t 0 ) of free TSP (70 nM) and incubated for 2 h at 4°C. In some wells, 125 I-GST-Tat was allowed to interact with immobilized heparin by a preliminary incubation of 1 h at 4°C, then TSP was added to the wells without changing the medium and incubated for a further 2 h at 4°C (ϩ 1 h). At the end of incubation, the amount of radioactivity associated to immobilized heparin was extracted and measured. In both panels, radioactivity bound to BSAcoated wells was subtracted from all values. Each point is the mean Ϯ se of 2 independent determinations in duplicate. activating activity of extracellular Tat when added up to 3 h after the administration of the trans-activating factor (30) .
We then evaluated the effect of TSP on cell internalization of Tat protein, a phenomenon that depends on the interaction of the trans-activating factor with cell surface HSPGs (refs 29 -31; M. Tyagi et al., unpublished observations). HL3T1 cells were treated with 125 I-GST-Tat in the presence of increasing concentrations of TSP. At the end of treatment, free 125 I-GST-Tat was removed, cells were lysed, and the amount of intracellular radioactivity was measured. In parallel experiments, HL3T1 cells were treated with the fluorescent chimera GST-Tat-GFP in the presence of increasing concentrations of TSP. At the end of treatment, free and cell surface-associated GST-Tat-GFP was removed, cells were fixed, and the amount of intracellular fluorescence was quantified by computerized image analysis (31) . As shown in TSP loses its capacity to inhibit the trans-activating activity of Tat when added to HL3T1 cells 30 min after the trans-activating factor (see Fig. 4B ). We evaluated the effect of a delayed TSP administration on cell internalization of GST-Tat-GFP. As shown in Fig. 5B , C, TSP inhibits the internalization of GSTTat-GFP only when added together with the fluorescent protein, being ineffective when added 1 h after GST-Tat-GFP administration. Under the same experimental conditions, heparin inhibits the internalization of GST-Tat-GFP both when added together with the fluorescent protein or 1 h after its administration (Fig. 5B) . These data indicate the ability of TSP to prevent but not disrupt the binding of Tat with cell surface HSPGs, which is required for cell internalization and LTR trans-activation (refs 29 -31; M. Tyagi et al., unpublished observations). This agrees with the in vitro observations showing that TSP inhibits the interaction of Tat with substrate-immobilized heparin but does not dissociate the protein from the glycosaminoglycan once the interaction has occurred (see Fig. 3B ).
TSP inhibits the mitogenic activity of Tat in murine adenocarcinoma T53 cells
To further characterize the Tat-antagonist activity of TSP, we evaluated its capacity to modulate the mitogenic activity exerted by extracellular Tat on T53 Tat-less cells. These cells were obtained in our laboratory (31) by subcloning the Tat-overexpressing T53 cell line originally established from adenocarcinoma of skin adnexa of Tat-transgenic mice (16, 64) . T53 Tatless cells do not produce significant amounts of extracellular Tat when compared to parental T53 cells, but still retain their capacity to proliferate when exposed to GST-Tat (Fig. 6A) . T53 Tat-less cells were treated with GST-Tat in the absence or presence of increasing concentrations of TSP. At the end of treatment, cells were trypsinized and counted. As shown in Fig. 6A , TSP inhibits the mitogenic activity of GST-Tat in a dosedependent manner (ID 50 equal to 3 nM) without affecting the basal proliferation induced in T53 Tat-less cells by 10% FCS. To investigate the time dependency of the inhibitory activity of TSP, the molecule was added to T53 Tat-less cells together with GST-Tat or 1 h after its administration. As shown in Fig. 6B , TSP exerts its inhibitory effect only when added to the cells together with the trans-activating factor. Under the same experimental conditions, heparin inhibits the mitogenic activity of GST-Tat independently of the time of administration.
In agreement with these observations, 100 nM TSP inhibits the binding of GST-Tat-GFP to T53 Tat-less cells (data not shown). As observed for Tat/HL3T1 cell interaction (see above), TSP exerts its inhibitory activity when added together with but not 1 h after GST-Tat-GFP administration. Under the same conditions, heparin inhibits the interaction of GST-Tat-GFP with T53 Tat-less cells independently of the time of administration (data not shown).
Our data indicate that exogenous recombinant GST-Tat exerts a mitogenic effect on T53 Tat-less cells that is inhibited by free TSP. Parental T53 cells are characterized instead by a high rate of basal proliferation due to the autocrine stimulation exerted by the endogenously synthesized Tat protein (16, 64) . This autocrine loop of stimulation can be interrupted by neutralizing anti-Tat antibodies or by Tat antagonists, including heparin and suramin (30, 31) . We investigated whether TSP can interfere with the autocrine loop of stimulation exerted by endogenous Tat in T53 cells. Parental T53 cells were incubated for 24 h in the absence or presence of increasing concentrations of TSP and then counted. As shown in Fig. 7A , TSP inhibits T53 cell proliferation in a dose-dependent manner, with an ID 50 equal to 10 nM. The inhibitory effect appears to be specific, since a different ECM component such as fibronectin does not affect significantly cell proliferation when tested at doses up to 100 nM. Also, TSP does not affect the basal proliferation of a clone of T53 cells (T53 TAT-AS clone 10) obtained by transfection with an antisense Tat cDNA (Fig. 7B) . These cells are characterized by a very limited production of Tat protein and a reduced, Tat-independent rate of cell proliferation when compared to parental T53 cells. Taken together, the data indicate that TSP inhibits T53 cell proliferation by acting on endogenously synthesized Tat protein released by the cells in the extracellular compartment.
TSP overexpression inhibits cell proliferation in T53 cells
T53 cells do not synthesize significant amounts of TSP (see below). To assess the effect of endogenous TSP on Tat-dependent cell proliferation, parental T53 cells were stably transfected with an expression vector harboring the full-length human TSP cDNA. Transfectants were first screened for Tat protein production and secretion by dot blot analysis of their conditioned media using specific anti-Tat antibodies. Only clones characterized by a production of Tat protein comparable to that of parental T53 cells were then subjected to a second screening for TSP expression and secretion by ELISA. Two clones, named T53-TSP-7 and T53-TSP-10 cells, were then selected and characterized further.
In detail, parental T53 cells and the two TSPtransfected clones secrete comparable amounts of Tat protein (0.6 -0.7 ng/ml/10 6 cells in 24 h). Also, T53-TSP-7 cells and T53-TSP-10 cells secrete in the medium 14 ng/ml and 65 ng/ml of TSP per 10 6 cells in 24 h, respectively, whereas parental T53 cells do not release detectable amounts of TSP. Figure 6 . Effect of TSP on the mitogenic activity of GST-Tat in T53 Tat-less cells. A) T53 Tat-less cells were seeded at 10,000 cells/cm 2 (arrow). After 24 h, they were incubated for a further 24 h with DMEM containing 10% FCS in the absence (E) or presence (F) of GST-Tat (2.7 nM) and increasing concentrations of TSP. At the end of treatment, cells were trypsinized and counted. Each point is the mean of 2 determinations in duplicate. se never exceeded 13% of the mean value. B) T53 Tat-less cells were treated as in panel A with GST-Tat (2.7 nM). Heparin (70 nM) and TSP (100 nM) were added to the cells together with GST-Tat (ϩ t 0 ) or 1 h after its addition (ϩ 1 h). At the end of treatment, cells were trypsinized and counted. Each point is the mean Ϯ se of 2-4 determinations in duplicate.
The two TSP-expressing clones were then compared to parental T53 cells for their rate of growth in vitro under basal culture conditions (Fig. 8A) . Both T53-TSP-7 and T53-TSP-10 cells are characterized by a rate of growth significantly lower than that of parental T53 cells, indicating that endogenously synthesized TSP has the capacity to inhibit the autocrine loop of stimulation exerted by Tat in T53 cells, as observed for exogenously added TSP.
TSP overexpression inhibits the angiogenic and tumorigenic capacity of T53 cells
T53 cells induce in vivo neovascularization that is inhibited by anti-Tat antibodies (32) . Moreover, the angiogenic activity of recombinant Tat can be inhibited by exogenously added TSP (58) . Also, T53 cells induce tumorigenesis when injected in nude and syngeneic mice with several T53-derived clones showing a tumorigenic capacity comparable to that of parental cells (16) . Since TSP has been demonstrated to inhibit angiogenesis and tumorigenesis in different in vivo models (48 -52), we compared the angiogenic and tumorigenic potential of parental T53 cells to that of T53-TSP-10 cells that express the highest levels of TSP.
In a first series of experiments, gelatin sponges adsorbed with parental T53 cells and T53-TSP-10 cells were implanted on the top of 8-day-old chick embryo CAMs. Sponges adsorbed with vehicle alone or with FGF2-overexpressing pZipFGF2 MAE cells (65) were used as negative and positive controls, respectively. CAMs were examined daily until day 12 when the angiogenic response was scored (Fig. 9) . T53 cells exert an angiogenic response similar to that exerted by FGF2-overexpressing cells when tested at 2 ϫ 10 4 or 6 ϫ 10 4 cells/sponge. In contrast, neovascularization induced by T53-TSP-10 cells is strongly reduced and comparable to that observed in vehicle-treated CAMs (Fig. 9) .
To evaluate the effect of TSP overexpression on the tumorigenic activity of T53 cells, parental T53 cells and T53-TSP-10 cells were injected s.c. in nude mice. As shown in Fig. 8B , tumors appeared rapidly (median 5 days, range 5-9 days) in mice injected with parental T53 cells and reached an average weight of 1.0 g at 5 wk. In contrast, injection of the same number of T53-TSP-10 cells resulted in the later appearance of slow-growing tumors (median 26 days, range 19 -33 days) that reached the weight of ϳ1.0 g at 7 wk.
Histological analysis performed on 5-wk-old lesions revealed that parental T53 tumors are characterized by tightly packed, poorly differentiated spindle-shaped cells with a limited stromal component and occasional small necrotic foci (Fig. 10a, c) . In contrast, T53-TSP-10 lesions show alveolar and tubular structures formed by more differentiated adenocarcinoma cells, with abundant stromal component and extensive areas of necrosis (Fig. 10b, d) . Immunohistochemical analysis showed a strong TSP immunoreactivity in T53-TSP-10 lesions, mainly associated with the stromal component (Fig. 10f) . A very faint TSP immunoreactivity was instead detected in tumors originated by parental T53 cells (Fig. 10e) . CD 31 immunostaining followed by microvessel counting demonstrated that the density of blood vessels in the stromal component of the tumors was reduced in T53-TSP-10 lesions when compared to parental T53 lesions (23Ϯ1 vs. 31Ϯ2 blood vessels/ field, respectively; PϽ0.001, Student's t test), with no major differences in vascularity of the neoplastic parenchyma (57Ϯ1 and 65Ϯ2 blood vessels/field for T53 and T53-TSP-10 tumors, respectively).
DISCUSSION
Here we demonstrate that TSP binds the GST-Tat protein with high affinity (K d equal to 25 nM). TSP/GST-Tat complex formation occurs either in solution and when one of the two proteins is immobilized to a substratum. The interaction is prevented at high ionic strength conditions (Ն 0.5 M NaCl) and by anti-Tat antibody or heparin. Instead, no binding was observed to GST devoid of the Tat moiety, thus confirming the specificity of the interaction of TSP with the trans-activating protein.
Previous observations had shown the ability of TSP to bind various growth factors and proteinases, including FGF2 (53), HGF (54), TGF-␤ (55) and PDGF (56) , with an affinity similar to that measured for Tat interaction. Note that most of the TSP ligands share with Tat the capacity to bind heparin/HS (54, 68 -69) and that heparin prevents their binding to TSP (53, 54) . Our finding that 1 mol of TSP binds 3 mol of Tat suggests that each TSP monomer binds one Tat molecule. Preliminary experiments have shown that FGF2 competes for the binding of GST-Tat to TSP, raising the possibility that similar molecular determinants are responsible for TSP interaction. Also, experimental evidences suggest that the TSP binding domain of Tat is located within the COOH terminus of the protein (M. Rusnati, unpublished observations), a region of the protein that contains the integrin binding domain of Tat (18) but is distinct from the basic domain responsible for KDR receptor (19) and heparin/HSPG (30, 33) interactions. Additional experiments are required to identify unambiguously the molecular bases of TSP/Tat interaction.
TSP inhibits cell internalization and HIV-LTR trans-activating activity of GST-Tat in HL3T1 cells. Also, TSP inhibits cell interaction and mitogenic activity of GST-Tat in T53 Tat-less cells. In all the assays, TSP exerts its antagonist activity with an ID 50 close to the K d of TSP/Tat interaction (25 nM). Cell surface binding of Tat occurs mainly through HSPGs (32, and M. Tyagi et al., unpublished observations) and here we have shown that TSP competes for the binding of GST-Tat to immobilized heparin. Taken together, our data strongly support the hypothesis that TSP exerts its inhibitory effect by binding and sequestering the trans-activating factor in the extracellular environment, thus hampering its capacity to interact with the cell surface and to exert its biological activity. We have recently demonstrated that TSP inhibits Tat-induced proliferation, chemotaxis, migration of endothelial cells in culture, and angiogenesis in vivo (58) . The mitogenic activity exerted by Tat in endothelial cells is inhibited by TSP with an ID 50 equal to 28 nM, in keeping with the proposed extracellular sequestration of Tat protein by TSP. In contrast, Tat-induced chemotaxis, migration, and angiogenesis are inhibited at much lower concentrations of TSP (0.02-0.2 nM), raising the possibility of alternative mechanisms of action. For instance, both Tat and TSP bind ␣ v ␤ 3 integrin (18, 36) , suggesting that TSP may also interfere with Tat/␣ v ␤ 3 interaction. Moreover, the ability of TSP to bind several proteases (57) may affect the capacity of Tat to modulate plasmin-dependent proteolysis (6) required during the neovascularization process.
TSP competes for the binding of GST-Tat to immobilized heparin when added together with the trans-activating factor, but is unable to dissociate the already formed Tat/heparin complex. Accordingly, TSP completely loses its antagonist ability when added to cell cultures 30 min after Tat administration. This capacity of TSP to prevent but not disrupt the interaction of Tat with heparin and cell surface HSPGs is of interest. Recently, we have demonstrated that Tat establishes a cooperative interaction with heparin in which the binding of the first Tat molecule facilitates the interaction of more Tat molecules to adjacent Tat binding regions of the glycosaminoglycan chain. This causes the formation of highly packed multimeric Tat/heparin complexes with a 100-fold increase of the affinity of the interaction (31). Thus, it is possible to hypothesize that TSP can prevent the formation of these complexes by binding to Tat and hampering its cooperative interaction with heparin/HS. However, TSP becomes ineffective once the multimeric high-affinity Tat/glycosaminoglycan complexes are formed. Accordingly, free heparin can prevent but not disrupt the interaction of immobilized TSP with Tat.
Although poorly present in plasma, TSP is found in serum after platelet activation and bound to ECM and cell surface HSPGs of many human tissues (36 -41) . Both free and immobilized TSP bind Tat. Heparin can destroy this interaction and the interaction of Tat with the cell surface (30 -32) . Finally, TSP prevents but does not disrupt the binding of Tat to heparin and cell surface. Thus, a scenario can be envisaged in which extracellular Tat may bind to free and cell-associated TSP and/or HSPGs. This will affect the bioavailability and biological activity of extracellular Tat differently depending on their relative concentrations and timing of interaction. It is worth noting that the release of HSPGs from the cell surface is strictly regulated by the plasmin system (68), which in turn can be modulated by TSP (46, 57) and Tat (6) . Thus, a complex and strictly regulated interplay may occur among Tat and the free or immobilized forms of TSP and HSPGs. This kind of spatial control has been already demonstrated for heparin/FGF2 interactions (68) and TSP/plasminogen interactions (57) .
T53 cells produce and secrete biologically active Tat protein, which in turn stimulates their proliferation in vitro in an autocrine manner and is responsible for their angiogenic and tumorigenic capacity in vivo (64) . T53 cells do not express detectable amounts of TSP. Here we have shown that their stable transfection with an expression vector harboring the full-length human TSP cDNA results in the production of TSP-expressing cells characterized by a reduced angiogenic potential in the CAM assay. This is in keeping with previous observations showing the capacity of TSP to exert an anti-angiogenic activity in different in vitro and in vivo models by interacting with angiogenic growth factors (53, 54) and endothelial cell receptors, including CD36 (70), and to inhibit angiogenesis induced by recombinant Tat protein in the murine Matrigel plug assay (58) .
We have also observed that TSP transfectants showed a reduced tumorigenic capacity when injected s.c. in nude mice. Xenografts were characterized by a longer latency and a reduced rate of growth when compared to lesions originated by parental T53 cells. This appears to be the consequence of the capacity of endogenous TSP to inhibit the autocrine loop of stimulation exerted by Tat protein in T53 cells. Indeed, TSP transfectants showed a reduced rate of growth in vitro similar to that observed in T53 Tat-less cells, in antisense Tat cDNA-transfected T53 TAT-AS clone 10 cells, and in parental T53 cells treated with exogenous TSP or with specific anti-Tat antibodies (64) . However, we cannot rule out the possibility that the anti-tumorigenic effect of TSP may also occur through mechanism(s) other than a direct, specific effect on extracellular Tat activity. Indeed, TSP has been demonstrated to reduce the tumorigenic potential of a wide spectrum of transformed cells mainly by inhibiting the neovascularization required for solid tumor growth (48, 49, 71) . Accordingly, TSP inhibits angiogenesis induced by Tat protein (58) as well as by a variety of angiogenic growth factors (54) . Thus, the moderate reduction of the microvascular density observed in the stroma of the xenografts originated by TSP transfectants may contribute to the reduced rate of growth of these tumors. Immunohistochemical analysis has shown that TSP accumulates in the stroma of the lesions induced by TSP transfectants. This may explain the restriction of the anti-angiogenic effect of TSP to the stromal component of these tumors. A stromal association of TSP has also been observed in TSP-overexpressing human squamous cell carcinoma xenografts (71) , in keeping with the ability of TSP to interact with ECM components (40 -42) . Finally, T53-TSP-10 tumors showed a more differentiated morphology when compared to T53 lesions, in keeping with the ability of TSP-overexpression to restore a normal phenotype in transformed endothelial cells (72) .
In conclusion, our data demonstrate that TSP interacts in vitro with extracellular Tat protein, exerting a potent antagonist activity on various biological activities of the trans-activating factor. Experimental evidences suggest that this interaction may be of importance also in vivo: 1) TSP inhibits the angiogenic and tumorigenic activity of Tat in different in vivo models (ref 56 and present study); 2) the K d of TSP/Tat interaction and the potency of the Tatantagonist activity of TSP measured in vitro are consistent with the concentration of TSP found in human serum [from 1 nM, as measured in normal serum (73) , to Ն 100 nM after platelet activation and in various pathological conditions (G. Taraboletti, unpublished observations)], thus indicating that the Tat-antagonist activity of TSP may be biologically relevant during AIDS where abnormal platelet activation occurs (74); 3) TSP inhibits with similar potency the 86 amino acid form of Tat and its 101 amino acid variant, with the latter representing the form most widely distributed among the different virus strains in vivo (67) .
Tat has been implicated in various AIDS-associated pathologies, including KS. Recent observations have demonstrated that KS lesions do not express TSP, leading to the hypothesis that TSP down-regulation might be permissive for the development of KS in AIDS patients (58, 75) . Also, Tat protein has been proposed as a target for AIDS therapy (76, 77) , leading to the development of anti-Tat vaccines (78) and synthetic Tat antagonists (30, 31, 79, 80) . Besides its Tat antagonist activity, TSP has been shown to block HIV infection by binding to gp120 (81) (82) . Even though additional studies are required to demonstrate unambiguously the capacity of TSP to interact with Tat in vivo and the relevance of this interaction for the biological activity of extracellular Tat in AIDS, our study suggests the potential use of TSP-derived peptides and/or peptido-mimetics as 'multi-target' compounds able to affect different aspects of HIV infection and AIDS-related disorders.
